Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Innocenti

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|March 7, 2003
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding studyC Bengala, R Danesi, V Guarneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patientsG Bocci, R Danesi, A D Di Paolo, et al.
The Pharmacogenomics Journal|March 18, 2015
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patientsS Chen, I Laverdiere, A Tourancheau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)C Bengala, I Pazzagli, F Innocenti, et al.
Hypertension (Dallas, Tex. : 1979)|December 26, 2001
Cardiac and vascular remodeling in older adults with borderline isolated systolic hypertension: the ICARe Dicomano StudyR Pini, M C Cavallini, F Bencini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancerP F Conte, E Baldini, A Gennari, et al.
The Pharmacogenomics Journal|April 15, 2015
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication studyD J Crona, J Ramirez, W Qiao, et al.
Therapeutic Drug Monitoring|August 15, 2000
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemiaF Innocenti, R Danesi, C Favre, et al.
International Journal of Radiation Oncology, Biology, Physics|April 5, 2001
The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University HospitalE Cellai, S M Magrini, G Masala, et al.
Transplantation Proceedings|September 8, 2004
Trends in mechanical ventilation and immediate extubation after liver transplantation in a single center in ChileM Quiroga, M G Rodríguez, C Montalván, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|March 7, 2003
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding studyC Bengala, R Danesi, V Guarneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patientsG Bocci, R Danesi, A D Di Paolo, et al.
The Pharmacogenomics Journal|March 18, 2015
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patientsS Chen, I Laverdiere, A Tourancheau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)C Bengala, I Pazzagli, F Innocenti, et al.
Hypertension (Dallas, Tex. : 1979)|December 26, 2001
Cardiac and vascular remodeling in older adults with borderline isolated systolic hypertension: the ICARe Dicomano StudyR Pini, M C Cavallini, F Bencini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancerP F Conte, E Baldini, A Gennari, et al.
The Pharmacogenomics Journal|April 15, 2015
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication studyD J Crona, J Ramirez, W Qiao, et al.
Therapeutic Drug Monitoring|August 15, 2000
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemiaF Innocenti, R Danesi, C Favre, et al.
International Journal of Radiation Oncology, Biology, Physics|April 5, 2001
The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University HospitalE Cellai, S M Magrini, G Masala, et al.
Transplantation Proceedings|September 8, 2004
Trends in mechanical ventilation and immediate extubation after liver transplantation in a single center in ChileM Quiroga, M G Rodríguez, C Montalván, et al.
Pageof 10